Bexxar

Active Ingredient(s): Tositumomab
FDA Approved: * June 27, 2003
Pharm Company: * CORIXA
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Bexxar Overview

Tositumomab is a murine monoclonal antibody which targets the CD20 antigen produced in mammalian cell.[1] It was combined with iodine-131 to produce a radiopharmaceutical for unsealed source radiotherapy, Iodine-131 Tositumomab (branded as Bexxar), for the treatment of non-Hodgkins lymphoma.[1] It is classified as a IgG2a lambda antibody.[1][2] The drug combination was developed by Corixa which was purchased by GlaxoSmithKline in...

Read more Bexxar Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Tositumomab

Recent Bexxar Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Bexxar: (1 result)

Sorted by National Drug Code

• 0007-3260 Bexxar Kit by Glaxosmithkline LLC

Other drugs which contain Tositumomab or a similar ingredient: (1 result)

• TOSITUMOMAB